EyePoint, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Eypt stock (EYPT) fell 12% today with $8.78M in trading volume. Insiders traded shares twice in 6 months, with 1 purchase and 1 sale. 89 hedge funds added shares, while 96 reduced positions. Analysts' median price target is $56.0.
Analysts reiterated Buy ratings for BridgeBio Pharma (BBIO) with a $120 price target, EyePoint Pharmaceuticals (EYPT) with a $17 target, and Abbott Laboratories (ABT) with a $125 target. BBIO and ABT have Strong Buy consensus, while EYPT has Moderate Buy.
EyePoint posted an updated investor presentation showing LUGANO Phase 3 DURAVYU topline results. While the full dataset did not achieve non-inferiority (NI) due to an asymmetric cohort, ad hoc analysis showed NI in BCVA. DURAVYU reduced treatment burden by 42% and had a favorable safety profile. EyePoint plans to file an NDA for wet AMD in H1 2027, pending positive LUCIA results and pre-NDA FDA engagement in Q4 2026.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning EYPT (EyePoint, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.
Recent EYPT coverage spans market movers, financial news and technology.
In the last 30 days, EYPT insiders filed 1 SEC Form 4 transaction — 1 purchase ($52K) and no sales. The most active reporter was Zaderej Karen L. with 1 filing.
The sharp intraday decline suggests short‑term pressure; no clear catalyst beyond market flow data.
Analyst reaffirmation with higher target could lift the stock modestly.
Positive Phase 3 data with non‑inferiority and reduced injection burden may boost valuation and drive near‑term buying interest.
Downgrade signals reduced upside amid clinical setbacks.
Sharp target cut signals significant downside risk.
AlphAI scores every news story that mentions EYPT with an AI model for sentiment and relevance, and aggregates insider trades from EyePoint, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Eypt stock (EYPT) fell 12% today with $8.78M in trading volume. Insiders traded shares twice in 6 months, with 1 purchase and 1 sale. 89 hedge funds added shares, while 96 reduced positions. Analysts' median price target is $56.0.
1 min readAnalysts reiterated Buy ratings for BridgeBio Pharma (BBIO) with a $120 price target, EyePoint Pharmaceuticals (EYPT) with a $17 target, and Abbott Laboratories (ABT) with a $125 target. BBIO and ABT have Strong Buy consensus, while EYPT has Moderate Buy.
2 min readEyePoint posted an updated investor presentation showing LUGANO Phase 3 DURAVYU topline results. While the full dataset did not achieve non-inferiority (NI) due to an asymmetric cohort, ad hoc analysis showed NI in BCVA. DURAVYU reduced treatment burden by 42% and had a favorable safety profile. EyePoint plans to file an NDA for wet AMD in H1 2027, pending positive LUCIA results and pre-NDA FDA engagement in Q4 2026.
1 min readEvercore initiates Lumentum (LITE) at Outperform with a $1,100 target, citing strong demand for Indium Phosphide lasers in AI. Jefferies upgrades Sempra Energy (SRE) to Buy, seeing undervaluation. TD Cowen downgrades Eyepoint (EYPT) to Hold, citing poor trial results. Truist downgrades Covista (CVSA) to Hold, citing valuation concerns. Baird upgrades Sonida Senior Living (SNDA) to Outperform, citing demographic trends.
3 min readMajor indices closed lower Tuesday due to war tensions and rising oil prices. The 30-year Treasury yield hit 5.27%, its highest since 2007, while Brent Crude surged 5% to $95. Analysts initiated coverage on Ally Financial (Strong Buy, $55 target) and GLOBAL FOUNDRIES (Buy, $60 target), among others.
3 min readUS stocks are mixed, with chipmakers and AI-infrastructure stocks rising, while software companies decline. Treasury Secretary Bessent announced upcoming economic measures against Iran. S&P 500 is tracking for 32% Q2 earnings growth, with 85% of companies beating estimates. Marvell (MRVL) and Sandisk (SNDK) lead gains, while Datadog (DDOG) and Salesforce (CRM) lead losses. Astera Labs (ALAB) and Onto Innovation (ONTO) received upgrades, while EyePoint (EYPT) plunged after a failed trial.
6 min readStock indices fluctuated as chipmakers rose while software companies declined. S&P 500 Q2 earnings are tracking at +32% growth, with AI infrastructure contributing 60%. Sandisk (SNDK) led gains, up +10%, while Datadog (DDOG) led losses, down -3%. EyePoint (EYPT) dropped -71% after a failed trial. Constellation Brands (STZ) fell -5% after Berkshire Hathaway sold its stake.
6 min readZaderej Karen L. purchased 10,600 shares of EyePoint, Inc. (EYPT) at $4.93 on 2026-08-18.
2 min readEyePoint Pharmaceuticals (EYPT) reported that its phase III study for Duravyu in wet age-related macular degeneration (wet AMD) missed the primary endpoint, causing shares to drop 67%. The study did not show non-inferiority to Regeneron's (REGN) Eylea in the full dataset, but Duravyu met key secondary endpoints, including a 42% reduction in treatment burden. The company plans to present additional data and awaits results from a second phase III study, LUCIA, expected in Q4 2026. EYPT shares have
5 min readAnalyst actions: DA Davidson upgraded Duolingo (DUOL) to Buy, PT $160 (from $130). Citi upgraded Bath & Body Works (BBWI) to Buy, PT $25. KeyBanc upgraded Acadia Realty Trust (AKR) to Overweight, PT $25. Mizuho downgraded Norwegian Cruise Line (NCLH) to Neutral, PT $17 (from $22). Multiple other upgrades/downgrades and initiations were issued across retail, real estate, telecom, and healthcare.
4 min read
